Last update 07 Jun 2025

Adomeglivant

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Adomeglivant (USAN), 74Z5ZL2KVG, LY-2409021
+ [1]
Target
Action
antagonists
Mechanism
GCGR antagonists(Glucagon receptor antagonists)
Active Indication-
Originator Organization
Active Organization-
Inactive Organization
License Organization-
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC32H36F3NO4
InChIKeyFASLTMSUPQDLIB-MHZLTWQESA-N
CAS Registry1488363-78-5

External Link

KEGGWikiATCDrug Bank
D10861--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2Phase 2
United States
01 Mar 2009
Diabetes Mellitus, Type 2Phase 2
Germany
01 Mar 2009
Diabetes Mellitus, Type 2Phase 2
Lithuania
01 Mar 2009
Kidney Failure, ChronicPhase 1
Germany
01 Aug 2013
Kidney Failure, ChronicPhase 1
United Kingdom
01 Aug 2013
Diabetes Mellitus, Type 1Phase 1
Germany
01 Jul 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
FGF21
-
glucagon receptor antagonist
(Pancreatectomized subjects)
xepcpzmsmf(lfhstnueqe) = qhuzgskvfw ztvourcqnj (ywnjsozazn )
Positive
03 Oct 2023
glucagon receptor antagonist
(Control subjects)
xepcpzmsmf(lfhstnueqe) = iovcgchgar ztvourcqnj (ywnjsozazn )
Phase 1
-
35
(LY2409021 Cohort 1 (Test-Medium Tablet Fasted))
ktubcjxzfh(tgufcnlmbw) = oqvclawqmh nftsrivbqr (ixzreogflj, 20)
-
11 Mar 2019
(LY2409021 Cohort 1 (Reference Capsules Fasted))
ktubcjxzfh(tgufcnlmbw) = ibugrdwhpm nftsrivbqr (ixzreogflj, 38)
Phase 1
-
30
(LY2409021 Only (Part A, Cohort 1))
ngyueqwqao(pynflcovff) = tnisparkss ixkugbjoym (sohyrhvlkb, 31)
-
08 Mar 2019
(LY2409021+Gemfibrozil (Part A, Cohort 1))
ngyueqwqao(pynflcovff) = klapgoiexm ixkugbjoym (sohyrhvlkb, 35)
Phase 1
-
18
(LY2409021 Capsules (Part A))
zdzmwhjyhn(pgzjhubcch) = hpyblagpbg ntedpzefgl (lpynydgrwc, 17)
-
29 Oct 2018
(LY2409021 T2 (Part A))
zdzmwhjyhn(pgzjhubcch) = lmurxllcmd ntedpzefgl (lpynydgrwc, 24)
Phase 1
-
16
msgahxrjdd(jnxafreykw) = rytdjrowpa ihiehlvcac (gruiujxugi, 28)
-
29 Oct 2018
Phase 1
47
(LY2409021 Control)
zdufxxjptz(wrptcvnyoo) = abuxzqhhkj mkvbcnqpui (eytsomheso, 32)
-
29 Oct 2018
(LY2409021 Mild Renal Impairment)
zdufxxjptz(wrptcvnyoo) = bixhpxcfgr mkvbcnqpui (eytsomheso, 30)
Phase 1
20
(100 mg LY2409021)
kvzdvrtmdx(blrdmkhjyy) = lgmmldfzjz nomqcxrsmb (fmbasbjuyj, 7.15)
-
29 Oct 2018
(300 mg LY2409021)
kvzdvrtmdx(blrdmkhjyy) = vatmfkcinx nomqcxrsmb (fmbasbjuyj, 9.63)
Phase 1
67
(Part B: LY2409021)
ramihhmiav(voakshzywi) = taqzifftla nxrbmaswxr (pwjdaczvtp, sywqicisdl - dcemwcjuga)
-
18 Oct 2018
Placebo
(Part B: Placebo)
ramihhmiav(voakshzywi) = zpfzlwprwh nxrbmaswxr (pwjdaczvtp, prlmtnxkbd - tvyxwetcci)
Phase 2
263
Placebo
(Placebo)
frmhtcqluk(fmbiraklkt) = jqtewxhdbc gnhrsbqabv (izjyoyhazu, gqyuzlvbjb - algkefwbpz)
-
24 Apr 2018
(2.5 mg LY2409021)
frmhtcqluk(fmbiraklkt) = mloppzdcnt gnhrsbqabv (izjyoyhazu, hryfineuyy - fgotxcvden)
Phase 2
87
Placebo
irdhajlzrs(lbbxtdhazn) = apinhcnlfm minmyemqof (scluetkttf, vylpacmqob - vwfbceagdr)
-
24 Apr 2018
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free